Only one-third of 12,565 patients eligible for the drugs got them -- even though they were treated at 201 hospitals that had voluntarily enrolled in the American Heart Association's Get with the Guidelines program.
Reasons why so few doctors "got with the program" are unclear. But the study authors offered some theories, from lack of marketing for the decades-old drugs to concerns about their safety.
The main drug studied, spironolactone, is a water pill that helps prevent kidneys from absorbing too much sodium, which can lead to excess fluid. In heart failure, water often builds up in lungs, blood and tissue because the heart can't pump properly.
The pills studied have been shown to reduce hospitalizations and deaths. But they also can be hard on the kidneys and when used in the wrong patients, side effects can be deadly -- another reason some doctors may avoid them.
The study found that inappropriate use -- in patients with signs of kidney trouble or other specific conditions -- was uncommon.
The study appears in Wednesday's Journal of the American Medical Association.
